Connectivity projects


Global SIM cards & diagnostic connectivity

FIND is working to bridge the gaps in diagnostic connectivity by establishing a low-cost mobile data service using global SIM cards.

In February 2018, FIND launched SIMplicity, a service powered by Telecom26 that provides reliable, global mobile data coverage at a low, fixed rate.

Quick links

Evaluating & enhancing connected diagnostics

The Connectivity Team at FIND has developed a set of programmes to promote, introduce and enhance connectivity in new and developing diagnostic products. From conception to implementation, the Team offers services to manufacturers to ensure optimal data collection and transfer from their diagnostic instruments.

Best practice guidance
Quality assurance
Performance testing
Trialling in settings of intended use

More effective use of diagnostic data in Myanmar

In Myanmar, FIND is working with health partners at district, regional and national levels to support the more effective use of data collected with diagnostic tools. FIND has partnered with the Clinton Health Access Initiative (CHAI) for this work.

Diagnostic instruments with data connectivity are a source of valuable information. Effectively used, the collected diagnostic data not only informs treatment decisions but can also help to determine population disease prevalence and trends, identify possible outbreaks, maintain diagnostic equipment and appropriately manage inventories of necessary health supplies, including medicines.

Where data are collected electronically, however, the vast amount can make it a daunting task to interpret, disseminate and use effectively. Correct use of collected data can also be hampered by other factors, such as a lack of available resources, infrequent training or inadequate operating procedures, which can limit the impact and benefits of connected diagnostics.

As a result of this project, which is being implemented in partnership with the Clinton Health Access Initiative (CHAI), FIND will support Myanmar’s health system to improve the usage of data from connected diagnostics across the spectrum of lab, clinical and management levels. Ultimately, this should increase health impact for patients and efficiencies within the health system.

  • This project is being conducted with the support of UK aid from the UK government, and with support of the Australian government.

Connectivity projects in India

The global roll-out of the GeneXpert MTB/RIF TB test – known in India as the cartridge-based nucleic acid amplification test (CBNAAT) – has changed the TB diagnostic landscape. More than 13 million tests have been performed in at least 116 countries since 2011, and the detection of multidrug-resistant TB (MDR-TB) has increased eight-fold compared to conventional testing.

Under its Revised National TB Control Programme’s (RNTCP) National Laboratory Scale-up Plan (2015 – 2019), India aims to attain the capacity needed to provide universal access to quality-assured diagnosis and follow-up for all forms of drug resistant-TB and all notified TB cases by the year 2019. Under this plan, 629 CBNAAT sites in the public health sector in India are now providing diagnosis for drug-susceptible TB and rifampicin-resistant TB.

FIND and the RNTCP have initiated a project to connect all CBNAAT machines in India for the purpose of remote data collection. Connectivity enhances patient data management, the quality assessment of testing, laboratory activity monitoring and disease surveillance. It also reduces the time it takes for patients to receive test results, leading to more rapid treatment and better care.

The Global Health Bureau, Office of Health, Infectious Disease and Nutrition (HIDN), US Agency for International Development, financially supports this project through Challenge TB under the terms of Agreement No. AID-OAA-A-14-00029. This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of Challenge TB and do not necessarily reflect the views of USAID or the United States Government.